Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erdheim-Chester Disease | 7 | 2020 | 8 | 1.470 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 24 | 1.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 342 | 0.920 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 20 | 0.870 |
Why?
|
| Splenic Neoplasms | 1 | 2022 | 17 | 0.850 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 106 | 0.780 |
Why?
|
| Histiocytic Disorders, Malignant | 2 | 2019 | 3 | 0.760 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 146 | 0.630 |
Why?
|
| Seroma | 1 | 2016 | 7 | 0.560 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 9 | 0.560 |
Why?
|
| Dermatomyositis | 1 | 2016 | 18 | 0.550 |
Why?
|
| Drug Discovery | 1 | 2017 | 107 | 0.540 |
Why?
|
| Protein Kinases | 1 | 2017 | 213 | 0.530 |
Why?
|
| Calcinosis | 1 | 2016 | 230 | 0.490 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 604 | 0.430 |
Why?
|
| Histiocytosis | 3 | 2019 | 7 | 0.360 |
Why?
|
| Mutation | 7 | 2024 | 4132 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 2 | 2020 | 55 | 0.340 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2020 | 29 | 0.340 |
Why?
|
| Neoplasms | 1 | 2023 | 3035 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 788 | 0.280 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 57 | 0.270 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2411 | 0.260 |
Why?
|
| Humans | 24 | 2024 | 89063 | 0.250 |
Why?
|
| Langerhans Cells | 1 | 2023 | 14 | 0.220 |
Why?
|
| Dendritic Cells | 2 | 2024 | 442 | 0.220 |
Why?
|
| Cyclin D3 | 1 | 2022 | 21 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 187 | 0.210 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 39 | 0.210 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 161 | 0.200 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 132 | 0.200 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 22 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1543 | 0.190 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 37 | 0.190 |
Why?
|
| Plasma Cells | 1 | 2021 | 84 | 0.190 |
Why?
|
| Middle Aged | 10 | 2024 | 25863 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 2020 | 691 | 0.180 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2020 | 6 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 197 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 2552 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2023 | 548 | 0.170 |
Why?
|
| Azetidines | 1 | 2019 | 37 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 162 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1796 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 170 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 102 | 0.160 |
Why?
|
| Oximes | 1 | 2018 | 16 | 0.160 |
Why?
|
| Female | 12 | 2024 | 46011 | 0.150 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2017 | 16 | 0.150 |
Why?
|
| Piperidines | 1 | 2019 | 164 | 0.150 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2017 | 4 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 145 | 0.150 |
Why?
|
| Erythroid Precursor Cells | 1 | 2017 | 33 | 0.150 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2017 | 18 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1521 | 0.150 |
Why?
|
| Imidazoles | 1 | 2018 | 148 | 0.140 |
Why?
|
| Aged | 7 | 2024 | 19077 | 0.140 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 30 | 0.140 |
Why?
|
| Adult | 8 | 2024 | 26507 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 51 | 0.140 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2016 | 12 | 0.140 |
Why?
|
| Lymphadenitis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 133 | 0.140 |
Why?
|
| ras Proteins | 1 | 2017 | 130 | 0.140 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 32 | 0.140 |
Why?
|
| Breast Implants | 1 | 2016 | 25 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2017 | 226 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 262 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6777 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 299 | 0.120 |
Why?
|
| Male | 9 | 2024 | 42251 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2018 | 410 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 665 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1149 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1241 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2863 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2020 | 135 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2021 | 354 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 835 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2017 | 3373 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9003 | 0.070 |
Why?
|
| Child | 3 | 2023 | 7149 | 0.060 |
Why?
|
| Phenotype | 2 | 2023 | 2439 | 0.060 |
Why?
|
| Macrophages | 2 | 2017 | 571 | 0.060 |
Why?
|
| Thrombopoiesis | 1 | 2023 | 5 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 6288 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2021 | 84 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 266 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 466 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 92 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1067 | 0.040 |
Why?
|
| Cerebellar Ataxia | 1 | 2020 | 22 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 91 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 48 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 336 | 0.040 |
Why?
|
| Mosaicism | 1 | 2017 | 70 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 214 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 123 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2017 | 76 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 8203 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2017 | 159 | 0.040 |
Why?
|
| Microglia | 1 | 2017 | 107 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2017 | 217 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 283 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 9237 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 370 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 218 | 0.030 |
Why?
|
| Animals | 3 | 2023 | 27317 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 93 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 285 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1591 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1363 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1135 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 11737 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1240 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1310 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 4273 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2362 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3443 | 0.020 |
Why?
|